U.S. markets close in 1 hour 17 minutes
  • S&P 500

    3,784.42
    -6.51 (-0.17%)
     
  • Dow 30

    30,295.33
    -20.99 (-0.07%)
     
  • Nasdaq

    11,131.00
    -45.40 (-0.41%)
     
  • Russell 2000

    1,756.55
    -19.22 (-1.08%)
     
  • Crude Oil

    87.64
    +1.12 (+1.29%)
     
  • Gold

    1,722.90
    -7.60 (-0.44%)
     
  • Silver

    20.60
    -0.49 (-2.34%)
     
  • EUR/USD

    0.9888
    -0.0098 (-0.98%)
     
  • 10-Yr Bond

    3.7610
    +0.1440 (+3.98%)
     
  • GBP/USD

    1.1337
    -0.0138 (-1.20%)
     
  • USD/JPY

    144.5130
    +0.3140 (+0.22%)
     
  • BTC-USD

    20,187.06
    +136.24 (+0.68%)
     
  • CMC Crypto 200

    457.32
    -1.09 (-0.24%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,120.53
    +128.32 (+0.48%)
     

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

·5 min read

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Mirati Therapeutics, Inc. (NASDAQ:MRTX) as an investment opportunity by estimating the company's future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. It may sound complicated, but actually it is quite simple!

Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

Check out our latest analysis for Mirati Therapeutics

The Model

We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:

10-year free cash flow (FCF) forecast

2023

2024

2025

2026

2027

2028

2029

2030

2031

2032

Levered FCF ($, Millions)

-US$638.8m

-US$538.6m

-US$246.7m

US$112.7m

US$165.6m

US$221.0m

US$274.0m

US$321.7m

US$362.7m

US$397.2m

Growth Rate Estimate Source

Analyst x5

Analyst x4

Analyst x4

Analyst x4

Est @ 46.96%

Est @ 33.46%

Est @ 24%

Est @ 17.38%

Est @ 12.75%

Est @ 9.51%

Present Value ($, Millions) Discounted @ 5.4%

-US$606

-US$485

-US$210

US$91.2

US$127

US$161

US$189

US$211

US$225

US$234

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = -US$62m

We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.9%. We discount the terminal cash flows to today's value at a cost of equity of 5.4%.

Terminal Value (TV)= FCF2032 × (1 + g) ÷ (r – g) = US$397m× (1 + 1.9%) ÷ (5.4%– 1.9%) = US$12b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$12b÷ ( 1 + 5.4%)10= US$6.8b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is US$6.8b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of US$84.8, the company appears quite good value at a 30% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out.

dcf
dcf

The Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Mirati Therapeutics as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.4%, which is based on a levered beta of 0.824. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, the DCF calculation shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Why is the intrinsic value higher than the current share price? For Mirati Therapeutics, there are three further factors you should further examine:

  1. Risks: Every company has them, and we've spotted 2 warning signs for Mirati Therapeutics you should know about.

  2. Future Earnings: How does MRTX's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.

  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here